Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: June 22, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 07, 2026
Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC).
Journal: Journal for immunotherapy of cancer
Published: April 07, 2026
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.
Journal: Cancer
Published: March 21, 2026
Longitudinal Phenotyping of Circulating Tumor Cells using a Scalable Deep Learning Framework.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 23, 2026
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 18, 2026
Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.
Journal: Journal for immunotherapy of cancer
Published: February 13, 2026
Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.
Journal: medRxiv : the preprint server for health sciences
Published: February 06, 2026
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 27, 2026
Quantifying partial pathological response rate in prostate cancer patients who underwent neoadjuvant chemotherapy using a novel morphometric approach.
Journal: Journal of pathology informatics
Published: September 02, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.
Journal: Investigational new drugs
Published: August 11, 2025
Last Updated: 09/26/2026